

Rogério A Lobo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3100558/publications.pdf>

Version: 2024-02-01

99
papers

9,134
citations

61984

43
h-index

51608

86
g-index

102
all docs

102
docs citations

102
times ranked

6837
citing authors

#	ARTICLE	IF	CITATIONS
1	Potential pitfalls of reproductive direct-to-consumer testing. <i>F&S Reports</i> , 2022, 3, 3-7.	0.7	2
2	Female Adult Acne and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee. <i>Journal of the Endocrine Society</i> , 2022, 6, bvac003.	0.2	23
3	Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 121-137.	3.1	33
4	A multicenter, randomized study to select the minimum effective dose of estetrol (E4) in postmenopausal women (E4Relief): part 1. Vasomotor symptoms and overall safety. <i>Menopause</i> , 2020, 27, 848-857.	2.0	30
5	Prevalence of metabolic disturbances among women with polycystic ovary syndrome in different regions of Brazil. <i>International Journal of Gynecology and Obstetrics</i> , 2020, 151, 383-391.	2.3	11
6	Kisspeptin Influence on Polycystic Ovary Syndrome – a Mini Review. <i>Reproductive Sciences</i> , 2020, 27, 455-460.	2.5	12
7	Menopause and Aging. , 2019, , 322-356.e9.		12
8	Evaluation of Hormonal Status. , 2019, , 887-915.e4.		8
9	Metabolic and cardiovascular effects of TX-001HR in menopausal women with vasomotor symptoms. <i>Climacteric</i> , 2019, 22, 610-616.	2.4	12
10	Characterization of metabolic changes in the phenotypes of women with polycystic ovary syndrome in a large Mediterranean population from Sicily. <i>Clinical Endocrinology</i> , 2019, 91, 553-560.	2.4	19
11	Impact of menopausal hormone formulations on pituitary-ovarian regulatory feedback. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2019, 317, R912-R920.	1.8	15
12	The Kronos Early Estrogen Prevention Study (KEEPS). <i>Menopause</i> , 2019, 26, 1071-1084.	2.0	97
13	Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and) Tj ETQq1 1 0.784324 rgBT /@verlock		
14	Low estradiol responses in oocyte donors undergoing gonadotropin stimulation do not influence clinical outcomes. <i>Journal of Assisted Reproduction and Genetics</i> , 2018, 35, 1675-1682.	2.5	6
15	Features of polycystic ovary syndrome (PCOS) in women with functional hypothalamic amenorrhea (FHA) may be reversible with recovery of menstrual function. <i>Gynecological Endocrinology</i> , 2018, 34, 301-304.	1.7	16
16	A 17 β -Estradiol + Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women. <i>Obstetrics and Gynecology</i> , 2018, 132, 161-170.	2.4	48
17	Utility of Ovarian Reserve Screening with Anti-Müllerian Hormone for Reproductive Age Women Deferring Pregnancy. <i>Journal of Women's Health</i> , 2017, 26, 345-351.	3.3	4
18	Effects of Oral vs Transdermal Estrogen Therapy on Sexual Function in Early Postmenopause. <i>JAMA Internal Medicine</i> , 2017, 177, 1471.	5.1	59

#	ARTICLE	IF	CITATIONS
19	Daniel R. Mishell Jr, MD, May 7, 1931â€“May 4, 2016. <i>Climacteric</i> , 2016, 19, 411-412.	2.4	1
20	Amh Measurement Versus Ovarian Ultrasound In The Diagnosis Of Polycystic Ovary Syndrome In Different Phenotypes. <i>Endocrine Practice</i> , 2016, 22, 287-293.	2.1	38
21	Pharmacogenomics of estrogens on changes in carotid artery intima-medial thickness and coronary arterial calcification: Kronos Early Estrogen Prevention Study. <i>Physiological Genomics</i> , 2016, 48, 33-41.	2.3	23
22	Back to the future: Hormone replacement therapy as part of a prevention strategy for women at the onset of menopause. <i>Atherosclerosis</i> , 2016, 254, 282-290.	0.8	105
23	Use of antiâ€“allergic hormone testing during ovarian reserve screening to identify women at risk of polycystic ovary syndrome. <i>International Journal of Gynecology and Obstetrics</i> , 2016, 135, 73-76.	2.3	1
24	Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPSâ€“Cognitive and Affective Study. <i>PLoS Medicine</i> , 2015, 12, e1001833.	8.4	330
25	Menopausal Hormonal Therapy and Cardiovascular Disease. <i>Current Obstetrics and Gynecology Reports</i> , 2014, 3, 217-222.	0.8	0
26	Laboratory Assessment. , 2014, , 822-850.e3.		10
27	Prevention of diseases after menopause. <i>Climacteric</i> , 2014, 17, 540-556.	2.4	197
28	Foreword. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2014, 142, 3.	2.5	0
29	Menopause and Aging. , 2014, , 308-339.e8.		5
30	Where Are We 10 Years After the Women's Health Initiative?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 1771-1780.	3.6	89
31	Genetic polymorphisms associated with carotid artery intima-media thickness and coronary artery calcification in women of the Kronos Early Estrogen Prevention Study. <i>Physiological Genomics</i> , 2013, 45, 79-88.	2.3	28
32	Consensus on womenâ€™s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. <i>Fertility and Sterility</i> , 2012, 97, 28-38.e25.	1.0	1,494
33	Does the level of serum antiâ€“allergic hormone predict ovulatory function in women with polycystic ovary syndrome with aging?. <i>Fertility and Sterility</i> , 2012, 98, 1043-1046.	1.0	21
34	Executive Summary of the Stages of Reproductive Aging Workshop + 10: Addressing the Unfinished Agenda of Staging Reproductive Aging. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1159-1168.	3.6	851
35	Emerging concepts about prenatal genesis, aberrant metabolism and treatment paradigms in polycystic ovary syndrome. <i>Endocrine</i> , 2012, 42, 526-534.	2.3	26
36	Different mechanisms for benefit and risk of coronary heart disease and stroke in early postmenopausal women. <i>Menopause</i> , 2011, 18, 237-240.	2.0	30

#	ARTICLE	IF	CITATIONS
37	Different mechanisms for benefit and risk of coronary heart disease and stroke in early postmenopausal women: a hypothetical explanation. <i>Menopause</i> , 2011, 18, 237-40.	2.0	21
38	The diagnosis of polycystic ovary syndrome in adolescents. <i>American Journal of Obstetrics and Gynecology</i> , 2010, 203, 201.e1-201.e5.	1.3	205
39	Climacteric commentaries. Endogenous estradiol and coronary calcifications in postmenopausal women. <i>Climacteric</i> , 2010, 13, 502-3.	2.4	0
40	Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. <i>Fertility and Sterility</i> , 2009, 92, 1025-1038.	1.0	239
41	<i>Menopause and Aging.</i> , 2009, , 325-355.		6
42	<i>Evaluation of Hormonal Status.</i> , 2009, , 801-823.		6
43	Metabolic syndrome in postmenopausal women: the influence of oral or transdermal estradiol on inflammation and coagulation markers. <i>American Journal of Obstetrics and Gynecology</i> , 2008, 199, 526.e1-526.e7.	1.3	12
44	Metabolic syndrome after menopause and the role of hormones. <i>Maturitas</i> , 2008, 60, 10-18.	2.4	224
45	Estrogen and progestogen use in postmenopausal women. <i>Menopause</i> , 2008, 15, 584-602.	2.0	211
46	FOREWORD. <i>Clinical Obstetrics and Gynecology</i> , 2008, 51, 533.	1.1	1
47	Surgical menopause and cardiovascular risks. <i>Menopause</i> , 2007, 14, 562-566.	2.0	112
48	<i>The Future of Therapy and the Role of Hormone Therapy.</i> , 2007, , 875-880.		1
49	Endothelial Dysfunction in PCOS: Role of Obesity and Adipose Hormones. <i>American Journal of Medicine</i> , 2006, 119, 356.e1-356.e6.	1.5	145
50	A comparison of oral and transdermal short-term estrogen therapy in postmenopausal women with metabolic syndrome. <i>Fertility and Sterility</i> , 2006, 86, 1669-1675.	1.0	69
51	Should symptomatic menopausal women be offered hormone therapy?. <i>MedGenMed: Medscape General Medicine</i> , 2006, 8, 40.	0.2	6
52	Should symptomatic menopausal women be offered hormone therapy?. <i>MedGenMed: Medscape General Medicine</i> , 2006, 8, 1 p preceding 35.	0.2	1
53	Appropriate use of hormones should alleviate concerns of cardiovascular and breast cancer risk. <i>Maturitas</i> , 2005, 51, 98-109.	2.4	9
54	Potential Options for Preservation of Fertility in Women. <i>New England Journal of Medicine</i> , 2005, 353, 64-73.	27.0	247

#	ARTICLE	IF	CITATIONS
55	Formulations and Use of Androgens in Women. Mayo Clinic Proceedings, 2004, 79, S3-S7.	3.0	13
56	Menopausal Sexual Interest Questionnaire (MSIQ): A Unidimensional Scale for the Assessment of Sexual Interest in Postmenopausal Women. Journal of Sex and Marital Therapy, 2004, 30, 235-250.	1.5	37
57	Evaluation of Cardiovascular Event Rates With Hormone Therapy in Healthy, Early Postmenopausal Women. Archives of Internal Medicine, 2004, 164, 482.	3.8	77
58	Does metformin induce ovulation in normoandrogenic anovulatory women?. American Journal of Obstetrics and Gynecology, 2004, 191, 1580-1584.	1.3	26
59	The Rationale for Low-Dose Hormonal Therapy. Endocrine, 2004, 24, 217-222.	2.2	16
60	Areas for future inquiry. Endocrinology and Metabolism Clinics of North America, 2004, 33, 761-769.	3.2	0
61	Elevated subclinical atherosclerosis associated with oophorectomy is related to time since menopause rather than type of menopause. Fertility and Sterility, 2004, 82, 391-397.	1.0	86
62	The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertility and Sterility, 2004, 81, 1498-1501.	1.0	141
63	Views on Recent Trials and the Future of Hormonal Therapy. Clinical Obstetrics and Gynecology, 2004, 47, 424-427.	1.1	1
64	Formulations and use of androgens in women. Mayo Clinic Proceedings, 2004, 79, S3-7.	3.0	0
65	What is the cardioprotective role of hormone replacement therapy?. Current Atherosclerosis Reports, 2003, 5, 56-66.	4.8	16
66	Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. Fertility and Sterility, 2003, 79, 1341-1352.	1.0	230
67	What are the key features of importance in polycystic ovary syndrome?. Fertility and Sterility, 2003, 80, 259-261.	1.0	24
68	Early ovarian ageing: a hypothesis: What is early ovarian ageing?. Human Reproduction, 2003, 18, 1762-1764.	0.9	16
69	The association of serum androsterone glucuronide with inflammatory lesions in women with adult acne. Journal of Endocrinological Investigation, 2002, 25, 765-768.	3.3	27
70	Postmenopausal hormone replacement therapy as antiatherosclerotic therapy. Current Atherosclerosis Reports, 2002, 4, 52-58.	4.8	11
71	A comparison of the relative efficacy of antiandrogens for the treatment of acne in hyperandrogenic women. Clinical Endocrinology, 2002, 57, 231-234.	2.4	63
72	Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertility and Sterility, 2001, 76, 13-24.	1.0	188

#	ARTICLE	IF	CITATIONS
73	Polycystic ovaries in hirsute women with normal menses. American Journal of Medicine, 2001, 111, 602-606.	1.5	90
74	Priorities in polycystic ovary syndrome. Medical Journal of Australia, 2001, 174, 554-555.	1.7	10
75	The Importance of Diagnosing the Polycystic Ovary Syndrome. Annals of Internal Medicine, 2000, 132, 989.	3.9	236
76	Normal Ovulatory Women with Polycystic Ovaries Have Hyperandrogenic Pituitary-Ovarian Responses To Gonadotropin-Releasing Hormone-Agonist Testing*. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 995-1000.	3.6	82
77	Polycystic Ovary Syndrome (PCOS): Arguably the Most Common Endocrinopathy Is Associated with Significant Morbidity in Women. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1897-1899.	3.6	417
78	Do hyperandrogenic women with normal menses have polycystic ovary syndrome?. Fertility and Sterility, 1999, 71, 319-322.	1.0	90
79	Evidence that insulin and androgens may participate in the regulation of serum leptin levels in women. Fertility and Sterility, 1999, 72, 926-931.	1.0	45
80	Alterations in low-density lipoprotein and high-density lipoprotein subclasses among hispanic women with polycystic ovary syndrome: influence of insulin and genetic factors. Fertility and Sterility, 1999, 72, 990-995.	1.0	53
81	Differences in Urinary Excretion Patterns of the hLH Beta Core Fragment in Premenopausal, Perimenopausal, and Postmenopausal Women. Menopause, 1999, 6, 290-298.	2.0	3
82	Polycystic Ovary Syndrome (PCOS): Arguably the Most Common Endocrinopathy Is Associated with Significant Morbidity in Women. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1897-1899.	3.6	94
83	Outcomes of High-Order Multiple Implantations in Women Undergoing Ovum Donation. Journal of Maternal-Fetal and Neonatal Medicine, 1997, 6, 268-272.	1.5	0
84	Outcomes of high-order multiple implantations in women undergoing ovum donation. , 1997, 6, 268-272.		3
85	Plasma lipids and desogestrel and ethinyl estradiol: a meta-analysis. Fertility and Sterility, 1996, 65, 1100-1109.	1.0	52
86	Endocrinology: Isolated polycystic morphology in ovum donors predicts response to ovarian stimulation*. Human Reproduction, 1995, 10, 524-528.	0.9	26
87	A disorder without identity: HCA, PCO, PCOD, PCOS, SLS. What are we to call it?!. Fertility and Sterility, 1995, 63, 1158-1160.	1.0	73
88	The route of administration influences the effect of estrogen on insulin sensitivity in postmenopausal women. Fertility and Sterility, 1994, 62, 1176-1180.	1.0	65
89	A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertility and Sterility, 1993, 60, 664-667.	1.0	183
90	Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome?. American Journal of Obstetrics and Gynecology, 1992, 167, 1807-1812.	1.3	399

#	ARTICLE	IF	CITATIONS
91	Is 11 ^β -hydroxyandrostenedione a better marker of adrenal androgen excess than dehydroepiandrosterone sulfate?. American Journal of Obstetrics and Gynecology, 1991, 165, 1837-1842.	1.3	45
92	CLINICAL REVIEW 27 Effects of Hormonal Replacement on Lipids and Lipoproteins in Postmenopausal Women. Journal of Clinical Endocrinology and Metabolism, 1991, 73, 925-930.	3.6	292
93	Lipids, clotting factors, and diabetes: Endogenous risk factors for cardiovascular disease. American Journal of Obstetrics and Gynecology, 1988, 158, 1584-1591.	1.3	23
94	6 Peripheral androgens and the role of androstenediol glucuronide. Clinics in Endocrinology and Metabolism, 1986, 15, 293-306.	1.6	57
95	Ovulation Induction in Clomiphene-Resistant Anovulatory Women: Differential Follicular Response to Purified Urinary Follicle-Stimulating Hormone (FSH) Versus Purified Urinary FSH and Luteinizing Hormone*. Journal of Clinical Endocrinology and Metabolism, 1985, 60, 922-927.	3.6	29
96	Evidence for the Importance of Peripheral Tissue Events in the Development of Hirsutism in Polycystic Ovary Syndrome*. Journal of Clinical Endocrinology and Metabolism, 1983, 57, 393-397.	3.6	175
97	Insulin resistance in polycystic ovary syndrome. American Journal of Obstetrics and Gynecology, 1983, 147, 588-592.	1.3	174
98	Clinical and laboratory predictors of clomiphene response**Supported in part by Grant HD 05932 from the National Institutes of Health, United States Public Health Service, Bethesda, Maryland, and by a grant from the Ford Foundation.. Fertility and Sterility, 1982, 37, 168-174.	1.0	143
99	Prolactin modulation of dehydroepiandrosterone sulfate secretion. American Journal of Obstetrics and Gynecology, 1980, 138, 632-636.	1.3	115